(PharmaNewsWire.Com, June 11, 2020 ) This industry is experiencing significant growth due to the rising incidence of cancer, developing infrastructure for cancer diagnosis, recommendation of cancer screening, availability of reimbursements, and increasing healthcare expenditure.
Easy accessibility to advanced technologies, government initiatives for screening cancer patients, favourable reimbursement scenario for pathology diagnostic tests, increasing healthcare expenditure, and high-quality infrastructure for hospitals and clinical laboratories are the major factors driving the growth of the tissue diagnostic market
The tissue diagnostics market size is expected to reach USD 4.7 billion by 2025 from USD 3.4 billion in 2020, at a CAGR of 6.5%. The rising incidence of cancer, growing healthcare expenditure, improving infrastructure of cancer diagnosis, and technological advancements in tissue diagnostics are driving the growth of the global market. North America is expected to register the highest growth rate during the forecast period mainly due to the advanced technologies, government initiatives for screening cancer patients
Consumables accounted for the largest share of the tissue diagnostic market, by product, in 2019
By product, the tissue diagnostic market is segmented into instruments and consumables. The consumables segment is expected to grow at the highest rate during the forecast period. The large market share of this segment is attributed to their requirement in large numbers, cost-effectiveness, and ease of use. The increasing number of reagent rental agreements is also one of the major factors driving the growth of the consumables market.
By technology, immunohistochemistry accounted for the largest market share in 2019
Based on the technology, the tissue diagnostic market is segmented into immunohistochemistry, in situ hybridization, digital pathology and workflow, and special staining. The immunohistochemistry segment is estimated to register the highest CAGR during the forecast period. This can primarily be attributed to is increasing prevalence of chronic diseases across the globe, where this technology is mostly used in tissue diagnostics.
By disease, the breast segment accounted for the largest market share in 2019
By disease, the market is categorized into breast cancer, gastric cancer, lymphoma, prostate cancer, NSCLC, and other diseases. The breast cancer segment is expected to grow at the highest rate during the forecast period. The rising incidence of breast cancer is the major driving factor of this segment.
Hospitals accounted for the largest share of the tissue diagnostic market, by end user, in 2019
The end user segment of this market is categorized into hospitals, pharmaceutical companies, research laboratories, contract research organizations, and other end users. The research laboratories segment is expected to grow at the highest growth rate during the forecast period. This can be attributed to increasing outpatient surgeries such as endoscopies performed in ambulatory surgical centers (ASCs) and physician offices, which has increased the number of samples outsourced to clinical laboratories. In addition, research laboratories also offer advantages such as excellent complex and specialized testing capabilities, efficient billing and collection systems, and low test costs
North America was the largest regional market for tissue diagnostic in 2019
This report covers the market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Of the four geographic regions studied in the report, North America is expected to register the highest growth rate during the forecast period mainly due to the advanced technologies, government initiatives for screening cancer patients.
Geographically, the tissue diagnostic market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2019, North America held the largest share of the market, followed by Europe. Easy accessibility to advanced technologies, government initiatives for screening cancer patients, favourable reimbursement scenario for pathology diagnostic tests, increasing healthcare expenditure, and high-quality infrastructure for hospitals and clinical laboratories in this region are the major factors driving the growth of the tissue diagnostic market in North America.
Leading Companies
The major players in the market include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), ABCAM (UK), Merck KGAA (Germany), BD (US), Hologic (US), Bio Rad (US), Biomeriux (France), Sakura Fientek Japan (Japan), BioSB (US), Biogenex (US), Cell Signaling Technology (US), Histoline Laboratories (Italy), Slee Medical GMBH (Germany), Amos Scientific PTY Ltd (Australia), Jinhua Yidi Medical Appliance Co.Ltd (China), Medite GMBH (Germany), Cellpath Ltd(UK), Dipath S.P.A. (Italy).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
